Large clinical trials designed to test the cardiovascular and renal safety of the new antidiabetic drug class of GLP-1 analogs surprisingly revealed that T2DM patients treated with liraglutide have fewer cardiovascular events than those treated with standard care (6) and do not affect renal function (12). Here, GLP1R is linked to type 2 diabetes mellitus.